Some evidence now supports a relationship between the expression of KLF17 and poor survival in human lung adenocarcinoma, hepatocellular carcinoma, gastric cancer, and papillary thyroid carcinoma [14,15,16,17]. Here, KLF17 is linked to hepatocellular carcinoma.